Searching. Please wait…
1443
37
172
30625
4483
2658
361
406
Abstract: Recommended post-liver transplant (LT) prophylaxis in patients with hepatitis delta includes a nucleos(t)ide analogue (NA) and anti-hepatitis B immunoglobulin (HBIG) indefinitely. We analysed the use of HBIG in real-life clinical practice and its impact on HBV/HDV recurrence in 174 HDV-related LT patients from 10 Spanish liver transplant centres (1988-2018). Median post-LT follow-up was 7.8 (2.3-15.1) years and patient survival at 5 years was 90%. Most patients (97%) received HBIG in the immediate post-LT, but only 42% were on HBIG at the last control. Among those discontinuing HBIG, the median time on treatment was 18 (7-52) months. Post-LT HBsAg+ was detected in 16 (9%) patients and HBV-DNA in 12 (7%). Despite HBsAg positivity, HDV recurrence was reported only in three patients (1.7%), all of whom were not receiving NA and had discontinued HBIG. Our data suggest that a finite HBIG prophylaxis in HDV-LT is feasible, especially if high-barrier NAs are used.
Fuente: Liver International, 2024, 44, 279-285
Publisher: Wiley-Blackwell
Year of publication: 2024
No. of pages: 7
Publication type: Article
DOI: 10.1111/liv.15777
ISSN: 1478-3223,1478-3231
Publication Url: https://doi.org/10.1111/liv.15777
SCOPUS
Citations
Google Scholar
Metrics
Read publication
RODRÍGUEZ-TAJES, SERGIO
GARCÍA-ELIZ, MARÍA
CABALLERO MARCOS, ARANTXA
CAMPOS-VARELA, ISABEL
CACHERO ROS, ALBA
LOINAZ, CARMELO
GÓMEZ BRAVO, MIGUEL Á.
RODRÍGUEZ-PERÁLVAREZ, MANUEL
EMILIO FABREGA GARCIA
GONZÁLEZ DIÉGUEZ, MARÍA L.
VINAIXA, CARMEN
PASCASIO, JOSÉ M.
FERNÁNDEZ VÁZQUEZ, INMACULADA
BALIELLAS, CARMEN
CASTELLS, LLUIS
SALCEDO, MAGDALENA
PRIETO, MARTÍN
CRESPO, GONZALO
LENS, SABELA
FORNS, XAVIER
Back